As of 2026-02-16, the Relative Valuation of 4D Molecular Therapeutics Inc (FDMT) is (63.33) USD. This relative valuation is based on P/E multiples. With the latest stock price at 9.25 USD, the upside of 4D Molecular Therapeutics Inc based on Relative Valuation is -784.7%.
The range of the Relative Valuation is (44.44) - (74.53) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 22.6x | 18.2x |
| Forward P/E multiples | 11.4x - 20.4x | 16.4x |
| Fair Price | (44.44) - (74.53) | (63.33) |
| Upside | -580.5% - -905.8% | -784.7% |
| Date | P/E |
| 2026-02-11 | -2.53 |
| 2026-02-10 | -2.49 |
| 2026-02-09 | -2.48 |
| 2026-02-06 | -2.46 |
| 2026-02-05 | -2.29 |
| 2026-02-04 | -2.54 |
| 2026-02-03 | -2.59 |
| 2026-02-02 | -2.50 |
| 2026-01-30 | -2.42 |
| 2026-01-29 | -2.45 |
| 2026-01-28 | -2.35 |
| 2026-01-27 | -2.32 |
| 2026-01-26 | -2.18 |
| 2026-01-23 | -2.17 |
| 2026-01-22 | -2.21 |
| 2026-01-21 | -2.10 |
| 2026-01-20 | -2.08 |
| 2026-01-16 | -2.06 |
| 2026-01-15 | -2.08 |
| 2026-01-14 | -2.39 |
| 2026-01-13 | -2.15 |
| 2026-01-12 | -2.05 |
| 2026-01-09 | -2.05 |
| 2026-01-08 | -1.99 |
| 2026-01-07 | -2.12 |
| 2026-01-06 | -1.96 |
| 2026-01-05 | -1.99 |
| 2026-01-02 | -2.00 |
| 2025-12-31 | -2.05 |
| 2025-12-30 | -2.07 |
| 2025-12-29 | -2.10 |
| 2025-12-26 | -2.18 |
| 2025-12-24 | -2.21 |
| 2025-12-23 | -2.16 |
| 2025-12-22 | -2.38 |
| 2025-12-19 | -2.37 |
| 2025-12-18 | -2.37 |
| 2025-12-17 | -2.52 |
| 2025-12-16 | -3.15 |
| 2025-12-15 | -2.99 |
| 2025-12-12 | -2.96 |
| 2025-12-11 | -2.98 |
| 2025-12-10 | -2.96 |
| 2025-12-09 | -2.87 |
| 2025-12-08 | -3.03 |
| 2025-12-05 | -2.92 |
| 2025-12-04 | -3.06 |
| 2025-12-03 | -2.92 |
| 2025-12-02 | -2.77 |
| 2025-12-01 | -2.87 |